Q-omics provides the consensus-scored RTEL1-TNFRSF6B profile across patient tissues and cancer cell-line models. RTEL1-TNFRSF6B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RTEL1-TNFRSF6B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RTEL1-TNFRSF6B RNA expression shows 19,545 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, COAD, and DLBC as cancer lineages where RTEL1-TNFRSF6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTEL1-TNFRSF6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTEL1-TNFRSF6B survival associations across molecular data types. RTEL1-TNFRSF6B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTEL1-TNFRSF6B RNA expression–survival associations across cancer types. High RTEL1-TNFRSF6B expression shows unfavorable associations in KIRC, KICH, ACC and COAD, but favorable associations in HNSC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RTEL1-TNFRSF6B RNA expression.
This table summarizes RTEL1-TNFRSF6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RTEL1-TNFRSF6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTEL1-TNFRSF6B shows higher tumor expression in COAD, KIRC, HNSC, STAD, LIHC and READ. The COAD box plot shows higher RTEL1-TNFRSF6B RNA expression in tumor versus normal tissue (log2 FC = +1.444, t-test p < 0.001).
This table shows molecular features associated with RTEL1-TNFRSF6B in patient tissues and cancer cell lines. In patient samples, RTEL1-TNFRSF6B shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, RTEL1-TNFRSF6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
